Pharmaceuticals

Fosun International Wins Five Awards at The Asset Corporate Sustainability Leadership Awards 2026, Upgraded to Platinum

HONG KONG, Oct. 13, 2026 /PRNewswire/ -- Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) today announced that it has been awarded the prestigious"Corporate Sustainability Leadership Awards 2026 – Platinum Award" by The Asset, a leading Asia-Pacific fi...

2026-10-13 12:46 8385

ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention

SHANGHAI, Oct. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling the company...

2026-10-13 09:00 3144

GCCL and LabConnect Sign MOU to Expand Global Clinical Trial Collaboration

Linking North American and Asia-Pacific Capabilities to Support Joint Sales and Project Execution SEOUL, South Korea and RALEIGH, N.C., Oct. 13, 2026 /PRNewswire/ -- GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced today that i...

2026-10-13 08:15 3411

SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease

LUCERNE, Switzerland and NEW DELHI, Oct. 13, 2026 /PRNewswire/ -- The SPARX Global Randomized Controlled Trial (RCT) has been officially initiated, marking the launch of the multinational randomized trial evaluating a drug-coated balloon (DCB)-first strategy against contemporary drug-eluting sten...

2026-10-13 02:11 3269

T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer

BEIJING, Oct. 12, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL ("T-MAXIMUM") today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate a Phase 2 clinical study of MT027, its internally developed, B7-H3-targeted universal (allogeneic) CAR-T therapy, for ...

2026-10-12 18:50 1987

New Opportunities for Global Cooperation: Kexing Biopharm Shines at CPHI Milan 2026

MILAN, Oct. 10, 2026 /PRNewswire/ -- From October 06 to 08, 2026, Kexing Biopharm (688136.SH) exhibited at CPHI Milan 2026, showcasing its global innovative drug pipeline, co-developed biosimilars, and a broad portfolio of products commercialized in overseas markets. During the event, the Company...

2026-10-10 16:06 4953

Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

SHANGHAI and HONG KONG, Oct. 9, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune di...

2026-10-09 11:22 4910

Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development

* Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead, Cancer Vaccines at Moderna, join Everest Medicines * Appointments support continued advancement of Everest's mRNA pip...

2026-10-09 10:15 5951

Telix to Host Capital Markets Day in Melbourne on November 4, 2026

MELBOURNE, Australia and INDIANAPOLIS, Oct. 9, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announced that it will host a Capital Markets Day in Melbourne, Australia, on Wednesday, November 4, 2026, from 9:00 a.m. to 12:30 p.m. (AEDT). Institutional i...

2026-10-09 04:00 2286

Rockwell Automation and Industry Leaders Launch the Digital CMC Consortium to Accelerate Digital Transformation in Pharmaceutical Development

New industry collaboration addresses pharma's most complex development challenges and expedites patient access to breakthrough therapies MILWAUKEE, Oct. 8, 2026 /PRNewswire/ -- Rockwell Automation, Inc.

2026-10-08 21:00 4276

LOTTE Biologics and Alvotech announce US-based manufacturing agreement to increase global supply

Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics' Syracuse facility in New York Strategic long-term partnership with Alvotech to increase their global manufacturing capacity and support growth in demand SEOUL, South Korea and REYKJAVIK, Iceland, Oct. 8, 202...

2026-10-08 19:17 2356

Sisram Medical Announces Share Repurchase Plan for Up to 1% of Issued Shares

Reinforcing Confidence in Long-Term Growth and Commitment to Shareholder Returns HONG KONG, Oct. 8, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices ("EBD"), injectables, and other complementary solutions, today an...

2026-10-08 18:16 6014

Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133

SUZHOU, China and MÖLNDAL, Sweden, Oct. 8, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the successful submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for RBD3133, a novel siRN...

2026-10-08 09:47 2277

OncoBayes progressing OB-001 to tackle ADC resistance and TKI brain penetration

LONDON, Oct. 7, 2026 /PRNewswire/ -- OncoBayes, a privately held clinical-stage pharmaceutical company, today announced the successful completion of preclinical work with OB-001, demonstrating the product's potential to tackle two major unmet needs in oncology: ADC resistance and the brain pen...

2026-10-07 14:00 2452

Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins

* Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2026 * The trial provided initial safety and tolerability data for Lu AF28996, with most treatment-emergent adverse events reported as mild...

2026-10-06 14:35 3257

Docquity Extends Asian Healthcare Intelligence to Japan Through Deepened Strategic Partnership with exMedio

Japan scale up advances Docquity's goal of Asian Healthcare Intelligence built on Clinical Intent, with Ask Dx as the core platform and "One Asia" linking physicians in Japan and Southeast Asia SINGAPORE, Oct. 6, 2026 /PRNewswire/ -- Docquity, the clinical AI platform for more than 75% of verifi...

2026-10-06 11:51 2681

Ajinomoto Bio-Pharma Services Unveils Refreshed Global Brand, Showcasing its Strength in Specialization

* Reflects the depth of expertise and innovation Aji Bio-Pharma brings to customers navigating increasingly demanding development and manufacturing challenges TOKYO, Oct. 5, 2026 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a global network of specialized contract developme...

2026-10-05 19:00 4627

AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)

The only known investigational therapy for SBMA in Phase 3 development worldwide * AJ201 (rosolutamide) is an investigational oral small molecule designed to address multiple disease mechanisms of spinal and bulbar muscular atrophy (SBMA, or Kennedy's disease) * Following submission of the Ph...

2026-10-05 12:30 2847

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 5, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global collab...

2026-10-05 05:46 4071
123456 ... 185